Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study

Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2009-03, Vol.100 (6), p.888-893
Main Authors: BERNEY, D. M, GOPALAN, A, GERALD, W, COOPER, C, SCARDINO, P, CUZICK, J, KUDAHETTI, S, FISHER, G, AMBROISINE, L, FOSTER, C. S, REUTER, V, EASTHAM, J, MØLLER, H, KATTAN, M. W
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens
Biological and medical sciences
Biomarkers
Biopsy
Cancer research
Cancer therapies
Cell cycle
Clinical Study
Humans
Immunohistochemistry
Ki-67 Antigen - analysis
Laboratories
Lymphatic system
Male
Medical prognosis
Medical research
Medical sciences
Metastasis
Middle Aged
Nephrology. Urinary tract diseases
Oncology
Pathology
Patients
Preventive medicine
Prognosis
Prostate cancer
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - mortality
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
Surveillance
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67 provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method, Deltachi(2) (1 d.f.)=24.6 (P
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6604951